Impact of homologous recombination deficiency (HRD) on outcomes with intraperitoneal (IP) and intravenous (IV) chemotherapy in ovarian cancer: Analyses from the translational iPocc study (TriPocc)

The iPocc randomised multicentre international study reported improved progression-free survival (PFS) but not overall survival (OS) with IP carboplatin and IV paclitaxel vs IV chemotherapy (chemo) in patients (pts) with epithelial ovarian, fallopian tube or primary peritoneal cancer. Previous studies suggested that pts with BRCA-deficient tumours may benefit from IP chemo. We conducted a non-prespecified analysis of the prognostic and predictive value of HRD in tissue samples retrospectively obtained from iPocc trial pts.